Welcome to our dedicated page for AKANDA news (Ticker: AKAN), a resource for investors and traders seeking the latest updates and insights on AKANDA stock.
Akanda Corp. (NASDAQ: AKAN) generates news across both the cannabis and telecommunications infrastructure sectors. Company announcements highlight its work through cannabis subsidiaries with operations in Canada, focused on cultivating and distributing medical cannabis and wellness products, as well as its activities through First Towers & Fiber Corp., a wholly owned subsidiary that develops and operates telecom towers and a dark fiber network in Mexico.
News updates about Akanda often cover regulatory and licensing developments in cannabis, such as operating under a hemp cultivation license in British Columbia, researching security requirements for a full cultivation license, and extending an option on a Canadian cultivation asset. These releases describe plans to develop THC and CBD assets, implement Health Canada–aligned security measures, and pursue milestones related to cultivation and product sales.
On the telecommunications side, Akanda’s news frequently focuses on First Towers’ infrastructure buildout in Mexico. Articles describe an existing base of approximately 30 operational revenue-generating towers and a 700-kilometer dark fiber network, long-term lease agreements, and participation as a preferred contractor in the Altán Redes Red Compartida national telecom project. Additional coverage details plans to construct or acquire up to 20 new towers, with the goal of strengthening coverage, increasing network capacity, and supporting recurring revenue.
Investors and observers can also find news on corporate and capital markets events, including special meetings of shareholders, share consolidations (reverse stock splits), proxy procedures, and commentary on broader cannabis policy developments. This news page brings together these updates so readers can follow how Akanda’s cannabis operations and telecom infrastructure initiatives evolve over time.
Akanda Corp. (NASDAQ: AKAN) and Tetra Bio-Pharma (TSX: TBP, OTCQB: TBPMF) announced a strategic supply agreement where Akanda will provide pharmaceutical-grade cannabis for Tetra’s QIXLEEF™ product. This partnership allows Akanda to enter the cannabinoid drug market and supports Tetra's FDA clinical trials for cancer pain management. The companies estimate a total addressable market of nearly $1.7 billion by 2028, with the supply commencing in Q3 2022 and potentially reaching over 10 metric tonnes annually.
Akanda Corp. (NASDAQ: AKAN) has announced a strategic partnership between its UK subsidiary, CanMart Ltd., Phlo Connect, and Cellen Life Sciences to launch a fully digital dispensing model for medical cannabis. This collaboration aims to enhance access to high-quality cannabis products for UK patients, minimizing prescription and delivery friction. The digital dispensing solution is now live, enabling patients to receive medications conveniently at home. CEO Tej Virk expressed confidence in expanding access to medical cannabis, addressing patient needs in the growing UK market.
Akanda Corp. (NASDAQ: AKAN) has successfully acquired Holigen Limited from Flowr Corporation (TSXV: FLWR, OTC: FLWPF) for approximately US$3.0 million in cash, 1.9 million common shares, and the assumption of US$4.3 million in non-recourse debt. This acquisition enhances Akanda's operational capacity and expands its seed-to-patient model in the EMEA region, aimed at meeting the increasing demand for medical cannabis. CEO Tej Virk stated that the acquisition positions Akanda as a leader in emerging cannabis markets, including adult-use opportunities.
Akanda Corp has announced an agreement to acquire Holigen Limited from Flowr Corporation for US$3 million in cash, plus shares and debt assumption. This acquisition will enhance Akanda’s operations in Europe, providing immediate EU GMP certification and expanding its product offerings with a high-quality genetics library. The deal aims to accelerate Akanda's seed-to-patient model, satisfying the growing demand for medical cannabis in emerging markets, and is expected to close in Q2 2022.
Akanda Corp. has completed its initial public offering (IPO) of 4,000,000 common shares at $4.00 each, raising a total of $16,000,000 in gross proceeds. The company intends to utilize these funds for property, plant, and equipment, operations, working capital, and general corporate purposes. Its shares are listed on The Nasdaq Capital Market under the ticker symbol 'AKAN,' effective March 15, 2022. Boustead Securities, LLC acted as the lead underwriter for this offering.
Akanda Corp. (NASDAQ: AKAN) has begun trading its common shares on The Nasdaq Capital Market, closing its first trading day at $10.50, above the offering price. The company priced its public offering of 4 million shares at $4.00 per share on
Akanda Corp (NASDAQ: AKAN) has commenced trading on The Nasdaq Capital Market, making it the first UK cannabis company with African operations to be listed. CEO Tej Virk highlighted the significance of this milestone for both the company and the industry, aiming to enhance patient access across the UK and Europe. The company plans to establish a 'seed-to-patient' model, emphasizing ethical business practices and community impact in Lesotho. Akanda aims to provide high-quality cannabis products and improve lives through increased access.